Balaxi Pharmaceuticals Reports Continued Solid Growth in Q1 FY23

Hyderabad, Telangana, India Revenue grows 42% in Q1FY23. ​Pharma Revenue in Latin America up 39%. Profit After Tax up 32% YoY. Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the first quarter of financial year

Related Keywords

Angola ,Telangana ,Andhra Pradesh ,India ,Dominican Republic ,Portugal ,United States ,Hyderabad ,Guatemala ,China ,American ,America ,Aashish Maheshwari ,Balaxi Pharmaceuticals Limited ,Balaxi Pharmaceuticals Ltd ,Balaxi Pharmaceuticals ,Pharma Revenue ,Latin America ,After Tax ,Pharmaceuticals Limited ,Per Share ,Financial Results ,Balaxi Healthcare ,Balaxi Global ,Profit After Tax ,Managing Director ,Latin American ,General Oral Solid Dosage ,Liquid Injection ,Balaxi ,Continued ,9mfy23 ,Growth ,Ipr Based Pharmaceutical ,Pharmaceutical Company ,Pharmaceuticals ,Reports ,Solid ,